Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reissued by analysts at Maxim Group in a research report issued on Friday.

TEVA has been the subject of several other research reports. Vetr lowered shares of Teva Pharmaceutical Industries Limited from a “strong-buy” rating to a “buy” rating and set a $31.94 target price for the company. in a report on Monday, May 22nd. Mizuho restated a “hold” rating and issued a $30.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Wednesday. Jefferies Group LLC restated a “hold” rating and issued a $33.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Friday, June 23rd. Credit Suisse Group lowered shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “neutral” rating in a report on Friday. Finally, CIBC reiterated a “buy” rating and set a $43.00 price objective on shares of Teva Pharmaceutical Industries Limited in a report on Friday, April 7th. One research analyst has rated the stock with a sell rating, twenty-two have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries Limited has a consensus rating of “Hold” and a consensus price target of $39.81.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 13.26% during trading on Friday, hitting $20.60. 93,317,085 shares of the stock traded hands. Teva Pharmaceutical Industries Limited has a 12 month low of $20.41 and a 12 month high of $55.45. The firm’s 50-day moving average price is $32.05 and its 200-day moving average price is $32.28. The stock has a market cap of $20.93 billion, a PE ratio of 264.10 and a beta of 0.46. Teva Pharmaceutical Industries Limited also was the recipient of unusually large options trading activity on Thursday. Stock traders purchased 66,716 put options on the stock. This represents an increase of approximately 864% compared to the typical volume of 6,922 put options.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to the consensus estimate of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.18% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.25 EPS. Analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.65 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Maxim Group Reiterates “Hold” Rating for Teva Pharmaceutical Industries Limited (TEVA)” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/06/maxim-group-reiterates-hold-rating-for-teva-pharmaceutical-industries-limited-teva.html.

Several hedge funds and other institutional investors have recently modified their holdings of the company. RiverPoint Capital Management LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 9.1% in the second quarter. RiverPoint Capital Management LLC now owns 15,836 shares of the company’s stock worth $526,000 after buying an additional 1,325 shares during the last quarter. Federated Investors Inc. PA increased its position in shares of Teva Pharmaceutical Industries Limited by 34,112.9% in the second quarter. Federated Investors Inc. PA now owns 228,542 shares of the company’s stock worth $7,592,000 after buying an additional 227,874 shares during the last quarter. FCA Corp TX purchased a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter worth about $266,000. Boston Private Wealth LLC increased its position in shares of Teva Pharmaceutical Industries Limited by 21.8% in the second quarter. Boston Private Wealth LLC now owns 10,472 shares of the company’s stock worth $348,000 after buying an additional 1,871 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its position in shares of Teva Pharmaceutical Industries Limited by 1.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 42,611 shares of the company’s stock worth $1,416,000 after buying an additional 611 shares during the last quarter. 56.20% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.